Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study-Reference-Cited by-同舟云学术

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

Published:2017-10 Issue:10 Volume:28 Page:2559-2566
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Calvo E.,Moreno V.,Flynn M.,Holgado E.,Olmedo M.E.,Lopez Criado M.P.,Kahatt C.,Lopez-Vilariño J.A.,Siguero M.,Fernandez-Teruel C.,Cullell-Young M.,Soto Matos-Pita A.,Forster M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/10/2559/24168898/mdx357.pdf

Reference19 articles.

1. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity;Leal;Br J Pharmacol,2010

2. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells;Santamaria Nunez;Mol Cancer Ther,2016

3. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models;Belgiovine;Br J Cancer,2017

4. DNA topoisomerasa targeting drugs: mechanisms of actions and perspectives;Malone;Anticancer Drugs,1997

5. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors;Elez;Clin Cancer Res,2014

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme;Internal Medicine Journal;2024-02-18

2. A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas;Current Treatment Options in Oncology;2024-02

3. Ling-Gui-Zhu-Gan decoction protects against doxorubicin-induced myocardial injury by downregulating ferroptosis;Journal of Pharmacy and Pharmacology;2024-01-18

4. Drug from Marine Sampling to Factory;Marine Ecology: Current and Future Developments;2023-11-02

5. Novel Therapeutic Options for Small Cell Lung Cancer;Current Oncology Reports;2023-10-23